What is Hytrin?
Hytrin was the brand of terazosin, an alpha-1 blocker used for symptomatic benign prostatic hyperplasia (BPH) and for high blood pressure. Hytrin tablets and capsules and the oral solution Tezruly are listed as discontinued, and terazosin is now supplied as generic capsules. Its main risk is a sharp fall in blood pressure with fainting after the first dose, after dose increases or when treatment restarts after a break, so it is always started at the lowest strength at bedtime.1
Approved products and generic therapeutic-equivalence ratings are listed in the FDA Orange Book.3
In BPH, terazosin relaxes smooth muscle in the bladder neck and prostate by blocking alpha-1 receptors, easing outlet obstruction without affecting how the bladder contracts.1
About 70% of men with BPH responded quickly with better urine flow and fewer symptoms, although its long-term effect on surgery or acute urinary blockage is not known.
Because prostate cancer causes similar symptoms and often coexists with BPH, men are examined to rule it out before treatment.
Like other alpha-1 blockers, it has been linked to intraoperative floppy iris syndrome during cataract surgery, so the eye surgeon should be told; stopping beforehand does not appear to help.
It has been added to diuretics and several beta-blockers in controlled trials without unexpected interactions, although extra blood-pressure drugs are added cautiously.
Terazosin is one of the blood pressure medicines; doxazosin and prazosin are other alpha-1 blockers.
